

Knobbe Martens Olson & Bear LLP*Intellectual Property Law***RECEIVED
CENTRAL FAX CENTER**

NOV 04 2005

2040 Main Street
Fourteenth Floor
Irvine, CA 92614
Tel 949-760-0404
Fax 949-760-9502
www.kmob.com**Facsimile Transmittal Sheet**

ORIGINAL WILL NOT FOLLOW

Confidentiality Notice:

The documents accompanying this facsimile transmission contain confidential information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us; and any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited.

TO: Commissioner for Patents
 USPTO FACSIMILE NO.: (571) 273-8300
 USPTO REFERENCE: Applicant: Haffner et al.
 Serial No.: 10/634,213
 Filed: August 5, 2003
 Title: DEVICES AND METHODS FOR GLAUCOMA
 TREATMENT

ATTORNEY: James W. Hill, M.D.
 PHONE NO.: (949) 760-0404
 ATTORNEY DOCKET NO.: GLAUKO.011CP1
 TOTAL PAGES: 12 (INCLUDING COVER SHEET)
 DOCKETING AGENT: Charlotte Disto-Masudal
 DATE: November 4, 2005

IF YOU DID NOT RECEIVE ALL OF THE PAGES, PLEASE CALL BACK IMMEDIATELY.

Facsimile Operator Phone Number: (949) 760-0404

Direct Line to Machine: (949) 760-9502

MESSAGE: ***Attached for filing in the above-referenced application are:***

Response Transmittal in 1 page; Response to Restriction Requirement in
 10 pages

2047823
110405San Diego
619.295.9500San Francisco
415.651.1111Los Angeles
213.554.2150Riverside
951.781.0771San Luis Obispo
805.547.5500

Knobbe Martens Olson & Bear LLP

Intellectual Property Law

RECEIVED
CENTRAL FAX CENTER

NOV 04 2005

2040 Main Street
Fourteenth Floor
Irvine, CA 92614
Tel 949-760-0404
Fax 949-760-9502
www.kmob.com

USPTO FACSIMILE TRANSMITTAL SHEET

Docket No.: GLAUKO.011CP1

CUSTOMER NO. 20995

Applicant : Haffner et al.
Appl. No. : 10/634,213
Filed : August 5, 2003
For : DEVICES AND METHODS FOR
GLAUCOMA TREATMENT
Examiner : Leslie R. Deak
Group Art Unit : 3761

CERTIFICATE OF FAX TRANSMISSION PTO CENTRALIZED FAX

I hereby certify that this correspondence and all marked attachments, are being transmitted via facsimile to the USPTO centralized Fax No. (571) 273-8300 on the date shown below:

November 4, 2005

(Date)

James W. Hill, M.D., Reg. No. 46,396

Transmitted herewith for filing and consideration in the above-referenced application are the following items:

(2) Response to Restriction Requirement in 10 pages.

FILING FEES:

FEE CALCULATION					
FEE TYPE		FEE CODE	CALCULATION	TOTAL	
Total Claims minus 20; or Previously Paid	51 - 51 = 0	1202 (\$50)	0 x 50 =	\$0	
Independent minus 3; or Previously Paid	15 - 15 = 0	1201 (\$200)	0 x 200 =	\$0	
SUB TOTAL				\$0	
The present application qualifies for Small Entity status under 37 CFR § 1.27. Fee reduced by 2.				(\$0)	
TOTAL FEE DUE				\$0	

Please charge the total fees due in the amount of \$0 to Deposit Account No. 11-1410.

The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410.

James W. Hill, M.D.
Registration No. 46,396
Attorney of Record
Customer No. 20,995
(949) 760-0404

2047790// 110405

San Diego
619 594 0000

San Francisco
415 774 4444

Los Angeles
213 594 3300

Riverside
951 704 0700

San Luis Obispo
805 547 8800

NOV 04 2005

GLAUKO:011CP1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Haffner et al.
Appl No.	: 10/634,213
Filed	: August 5, 2003
For	: DEVICES AND METHODS FOR GLAUCOMA TREATMENT
Examiner	: Leslie R. Deak
Group Art Unit	: 3761

RESPONSE TO RESTRICTION REQUIREMENT DATED OCTOBER 5, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In the above-reference application, please consider the following amendments and remarks in response to the restriction requirement dated October 5, 2005:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 9 of this paper.